Baheal Medical plans to introduce innovative drugs for idiopathic pulmonary fibrosis
According to reports, Baheal Medical announced that it has signed a strategic cooperation agreement with Tianjin Jikun Pharmaceutical Technology Co., Ltd.; under the agreement, when Jikun Pharmaceutical's research product JK1033 reaches a certain development stage, Baheal Medical has the right to acquire JK1033 at a reasonable price agreed upon by both parties. JK1033 is a small molecule compound that treats idiopathic pulmonary fibrosis through a novel mechanism of action. Additionally, Baheal Medical revealed that the company will also strategically invest in Jikun Pharmaceutical, intending to hold a 24% stake
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments